Har­vard con­sor­tium blue­prints $50M cell and gene ther­a­py cen­ter — but can they ac­tu­al­ly fos­ter low­er drug prices?

Har­vard is spear­head­ing a con­sor­tium that has set out to build a $50 mil­lion cen­ter aimed at quick­en­ing the de­vel­op­ment of new and far more ef­fi­cient cell and gene ther­a­pies in the boom­ing Boston biotech hub. And the group plans to move fast.

The Cen­ter for Ad­vanced Bi­o­log­i­cal In­no­va­tion and Man­u­fac­tur­ing is aim­ing at build­ing a 30,000 to 40,000 square foot fa­cil­i­ty in Boston where drug hunters can work on next-gen ther­a­pies in the field — like the off-the-shelf CAR-T drugs look­ing to sup­plant the com­plex au­tol­o­gous pi­o­neers now on the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER